MedTrace Logo

A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease

NCT01923584 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-09-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of EPI-743 in patients with Parkinson's disease.

Conditions

Interventions

DRUG

EPI-743 400mg

DRUG

EPI-743 200mg

Sponsors & Collaborators

  • Edison Pharmaceuticals Inc

    collaborator INDUSTRY

  • University of South Florida

    lead OTHER

Principal Investigators

  • Theresa Zesiewicz, MD · University of South Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2015-12-31
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01923584 on ClinicalTrials.gov